Full-Time

Quality Assurance Computerized Systems

LFB

LFB

1,001-5,000 employees

Public health biopharmaceuticals via plasma-derived products

No salary listed

Arras, France

Hybrid

Up to two remote-work days per week after four months of service.

Bachelor's

Category
Biology & Biotech (1)
Required Skills
GMP
Quality Assurance (QA)
Excel/Numbers/Sheets

Get referred to LFB

See people who can refer or advise you

Requirements
  • A Bac+5-level education in industrial information technology, engineering, quality, or an equivalent field.
  • At least three years of experience validating computerized systems in the pharmaceutical industry.
  • Strong knowledge of regulatory requirements, including GAMP 5, Annex 11, and 21 CFR Part 11.
  • Ability to independently write and execute validation deliverables.
  • Previous experience in a Good Manufacturing Practice environment.
  • Rigor, structure, and organization.
  • Strong interpersonal skills for interacting with information technology, quality, and production teams.
  • Ability to independently take ownership of a defined scope.
Responsibilities
  • Maintain and update the site's computerized-systems inventory and Excel-file inventory.
  • Approve validation strategies and validation plans for computerized systems.
  • Support the management of technical shutdown documentation and periodic reviews of computerized systems.
  • Contribute to business solutions involving computerized systems and ensure that they meet regulatory requirements.
  • Support the preparation and approve computerized-systems validation documents, including user requirements specifications, risk analyses, traceability matrices, specifications, protocols, reports, installation qualification, operational qualification, performance qualification, and associated deviations and corrective and preventive actions.
  • Support information-systems validation teams for computerized systems and automation equipment in site production and laboratory operations.
  • Provide regulatory support to information-systems validation teams for the site's industrial information-technology infrastructure, including networks, servers, and virtualization.
  • Verify and approve the validation of the site's computerized systems and GxP Excel files.
  • Perform risk analyses with system owners and data owners and implement mitigation plans.
  • Act as the primary Quality Assurance contact for nonconformities, including deviations, qualification events, change controls, and corrective and preventive actions, related to information systems.
  • Provide support and expertise for the handling of data-integrity nonconformities across teams.
  • Support change-control, deviation, corrective-and-preventive-action, and documentation quality processes within the scope, primarily for site industrial information technology.
  • Review and approve system access and audit trails, and support backup and restoration processes.
  • Participate in audits and inspections as a subject-matter expert on computerized-systems validation and data-integrity matters.

LFB is a French biopharmaceutical company that develops and manufactures medicines from plasma and biotech products. It collects plasma, fractionates it into medicines, and also produces recombinant proteins for rare diseases in immunology and hemostasis, sold in many countries. It stands out because it started as a state-initiated public health mission and remains state-owned with the French State as sole shareholder, plus vertical integration through acquisitions of plasma collection firms. Its goal is to ensure a reliable supply of essential medicines for public health while growing as a global biopharma player.

Company Size

1,001-5,000

Company Stage

N/A

Total Funding

N/A

Headquarters

Courcebœufs, France

Founded

1994

Get referred to LFB

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Arras released first medicines in 2025, proving commercialization after heavy capital spending.
  • LFB signed a 2026 collaboration with Sartorius to accelerate client programs and GMP manufacturing.
  • France 2030 funding and the 2026 Alès expansion add capacity and roughly fifty jobs.

What critics are saying

  • EFS must raise plasma collections to 1.4 million liters by 2028 or Arras underutilizes.
  • LFB BIOMANUFACTURING still depends on Sartorius for cell line development, limiting full-stack control.
  • A single French industrial base creates existential exposure to contamination, recalls, or regulatory shutdowns.

What makes LFB unique

  • French state-owned sole domestic plasma fractionator anchors national medicine supply.
  • Arras plant, authorized in 2025, centralizes production and triples plasma-derived capacity.
  • Europlasma and Amber Plasma give LFB 24 Central European collection centers.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

401(k) Retirement Plan

Remote Work Options

Unlimited Paid Time Off

Flexible Work Hours

Paid Vacation

Hybrid Work Options

Wellness Program

Mental Health Support

Phone/Internet Stipend

Home Office Stipend

Stock Options

Company Equity

Conference Attendance Budget

Family Planning Benefits

Fertility Treatment Support

Professional Development Budget

Education allowance

Tuition Reimbursement

Growth & Insights and Company News

Headcount

6 month growth

7%

1 year growth

7%

2 year growth

6%
MyPharma Editions
May 30th, 2024
LFB Acquires Amber Plasma in Czech Republic

Title: "LFB Acquires Amber Plasma in the Czech Republic" LFB and its subsidiary Europlasma have acquired Amber Plasma, which operates 12 plasma collection centers in the Czech Republic. This acquisition increases Europlasma's total to 24 centers in Central Europe, enhancing LFB's plasma collection capacity. The move supports LFB's goal to meet growing patient demand and will aid in the launch of a new production site in Arras, France, tripling its medication production capacity.